We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Denosumab‐Related Osteonecrosis of the Jaw May Not Be a Subject of Teriparatide Treatment.
- Authors
Park, Kyung‐Su; Jung, Seung Min; Park, Yune‐Jung; Kim, Ki‐Jo
- Abstract
This risk of bone loss makes teriparatide unsuitable for the treatment of denosumab-related ONJ in patients with osteoporosis. To the Editors: We read with great interest the recent article by Everts-Graber and colleagues regarding the higher risk of osteonecrosis of the jaw (ONJ) under denosumab compared to bisphosphonates (BPs) in patients with osteoporosis. SP ( sp 1 SP ) sp It was also reported that the risk of developing ONJ in patients with cancer and bone metastases was significantly higher in the denosumab group than in the zoledronic acid group. SP ( sp 2,3 SP ) sp Teriparatide has been considered an effective therapeutic modality for medication-related ONJ in previous reports. SP ( sp 4-6 SP ) sp However, there are certain concerns about using teriparatide for the treatment of ONJ and osteoporosis thereafter in patients who have developed denosumab-related ONJ. Because many patients experience a rebound effect of multiple vertebral fractures after the discontinuation of denosumab, SP ( sp 8 SP ) sp immediate subsequent therapy with a BP is strongly recommended. SP ( sp 9 SP ) sp However, BPs cannot be used in patients with ONJ.
- Subjects
TERIPARATIDE; OSTEONECROSIS; JAWS
- Publication
Journal of Bone & Mineral Research, 2022, Vol 37, Issue 10, p2044
- ISSN
0884-0431
- Publication type
Article
- DOI
10.1002/jbmr.4625